Published in Atherosclerosis on November 01, 1990
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest (1993) 1.17
Serum lipids, lipoproteins and apolipoproteins in pregnant non-diabetic patients. J Clin Pathol (1994) 1.14
Characterization of drug-protein interactions in blood using high-performance affinity chromatography. J Sep Sci (2009) 1.13
Characterization of drug interactions with serum proteins by using high-performance affinity chromatography. Curr Drug Metab (2011) 1.09
Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med (2004) 1.08
Analysis of drug interactions with high-density lipoprotein by high-performance affinity chromatography. Anal Biochem (2009) 1.00
Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis (1997) 0.96
Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ (1991) 0.86
Identification and analysis of stereoselective drug interactions with low-density lipoprotein by high-performance affinity chromatography. Anal Bioanal Chem (2012) 0.85
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
Effect of Nandrolone Decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients. Lipids Health Dis (2004) 0.77
Analysis of drug interactions with very low density lipoprotein by high-performance affinity chromatography. Anal Bioanal Chem (2014) 0.76
Prevalence of microalbuminuria, lipoprotein (a) and coronary artery disease in the lipid clinic. J Clin Pathol (1996) 0.75
Analysis of Drug Interactions with Lipoproteins by High-Performance Affinity Chromatography. Adv Med Biol (2012) 0.75
Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. J Clin Pathol (1993) 0.75
Does lipoprotein (a) level have a predictive value in restenosis after coronary stenting? Int J Prev Med (2011) 0.75
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest (2002) 1.52
HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis (1995) 1.48
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
Effect of pectin on serum lipids and lipoproteins, whole-gut transit-time, and stool weight. Lancet (1976) 1.12
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol (2000) 1.08
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest (2000) 1.03
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) (2000) 0.98
Frequency of citation and outcome of cholesterol lowering trials. BMJ (1992) 0.98
Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract (2003) 0.98
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet (1999) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2008) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. Ann Rheum Dis (2005) 0.94
Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun (2000) 0.93
Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis (2004) 0.93
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2005) 0.93
Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest (2000) 0.92
Paraoxonase and coronary heart disease. Curr Opin Lipidol (1998) 0.90
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med (2002) 0.90
Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr (1994) 0.90
The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol (2002) 0.90
A comparison of methods for the immunoassay of serum apolipoprotein B in man. Clin Chim Acta (1976) 0.89
Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis (1992) 0.89
Fetal and maternal lipoprotein metabolism in human pregnancy. Clin Sci (Lond) (1995) 0.89
Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens (1998) 0.89
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) (1993) 0.89
Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. Atherosclerosis (1991) 0.88
Costs of aspirin and statins in general practice. QJM (2002) 0.88
Clinical aspects of hyperlipidaemia. Br J Hosp Med (1984) 0.88
Apolipoprotein E genotyping in Alzheimer's disease. Lancet (1996) 0.88
Effect of phenobarbitone on plasma apolipoprotein B and plasma high-density-lipoprotein cholesterol in normal subjects. Clin Sci (Lond) (1979) 0.87
Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis (2003) 0.87
Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabet Med (1991) 0.86
The assessment of Achilles tendon size in primary hypercholesterolaemia by computed tomography. Atherosclerosis (1982) 0.86
Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus. J Clin Endocrinol Metab (1998) 0.86
Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. QJM (2008) 0.86
Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta (1980) 0.86
Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridaemic patients and in normal men. Clin Sci (Lond) (1985) 0.85
Lipoprotein (a) and microvascular disease in type 1 (insulin-dependent) diabetes. Diabet Med (1991) 0.85
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis (2009) 0.85
Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. Arterioscler Thromb (1992) 0.84
Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM (2002) 0.84
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med (2004) 0.84
Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med (1990) 0.83
Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron (1997) 0.83
All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis (2010) 0.83
Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta (1990) 0.82
Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet (1995) 0.82
Elevation of skeletal muscle isoform of serum creatine kinase in heterozygous familial hypercholesterolaemia. J Intern Med (1990) 0.82
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2007) 0.81
Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun (1998) 0.81
Serum and urinary high density lipoproteins in glomerular disease with proteinuria. Kidney Int (1986) 0.81
Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta (1978) 0.81
Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis (1993) 0.80